Suchen
Prothena Corporation PLC
PRTAZur Watchlist hinzufügen
8.120USD
-0.290-3.45%
Handelsschluss 07-31 16:00（ET）Kurse um 15 Minuten verzögert
425.11MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Prothena Corporation PLC Unternehmen
Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.
Prothena Corporation PLC Informationen
BörsenkürzelPRTA
Name des UnternehmensProthena Corporation PLC
IPO-datumDec 21, 2012
CEOKinney (Gene G)
Anzahl der mitarbeiter163
WertpapierartOrdinary Share
GeschäftsjahresendeDec 21
Addresse77 Sir John Rogerson's Quay, Block C
StadtDUBLIN
BörseNASDAQ OMX - NASDAQ BASIC
LandIreland
PostleitzahlD02 VK60
Telefon35312362500
Websitehttps://www.prothena.com/
BörsenkürzelPRTA
IPO-datumDec 21, 2012
CEOKinney (Gene G)
Führungskräfte von Prothena Corporation PLC
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Brandon S. Smith
Mr. Brandon S. Smith
Chief Operating Officer
Chief Operating Officer
130.00K
--
Dr. Wagner M. Zago, Ph.D.
Dr. Wagner M. Zago, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
85.00K
--
Dr. Dennis J. Selkoe, M.D.
Dr. Dennis J. Selkoe, M.D.
Independent Director
Independent Director
4.21K
--
Mr. Richard T. Collier
Mr. Richard T. Collier
Independent Director
Independent Director
1.22K
--
Dr. Lars G. Ekman, M.D., Ph.D.
Dr. Lars G. Ekman, M.D., Ph.D.
Chairman Emeritus
Chairman Emeritus
243.00
--
Mr. Tran B. Nguyen
Mr. Tran B. Nguyen
Chief Financial Officer, Chief Strategy Officer
Chief Financial Officer, Chief Strategy Officer
--
--
Dr. Gene G. Kinney, Ph.D.
Dr. Gene G. Kinney, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Karin L. Walker, CPA
Ms. Karin L. Walker, CPA
Chief Accounting Officer
Chief Accounting Officer
--
--
Ms. Paula K. Cobb
Ms. Paula K. Cobb
Independent Director
Independent Director
--
--
Mr. Michael J. Malecek, J.D.
Mr. Michael J. Malecek, J.D.
Chief Legal Officer, Company Secretary
Chief Legal Officer, Company Secretary
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Brandon S. Smith
Mr. Brandon S. Smith
Chief Operating Officer
Chief Operating Officer
130.00K
--
Dr. Wagner M. Zago, Ph.D.
Dr. Wagner M. Zago, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
85.00K
--
Dr. Dennis J. Selkoe, M.D.
Dr. Dennis J. Selkoe, M.D.
Independent Director
Independent Director
4.21K
--
Mr. Richard T. Collier
Mr. Richard T. Collier
Independent Director
Independent Director
1.22K
--
Dr. Lars G. Ekman, M.D., Ph.D.
Dr. Lars G. Ekman, M.D., Ph.D.
Chairman Emeritus
Chairman Emeritus
243.00
--
Mr. Tran B. Nguyen
Mr. Tran B. Nguyen
Chief Financial Officer, Chief Strategy Officer
Chief Financial Officer, Chief Strategy Officer
--
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Prothena Corporation PLC?
Die fünf größten Anteilseigner von Prothena Corporation PLC sind: Mr. Brandon S. Smith
Wie viele Institutionen halten Anteile an Prothena Corporation PLC (PRTA)?
Mit Stand vom 2026Q1 halten 436 Institutionen Anteile an Prothena Corporation PLC, mit einem Gesamtmarktwert von etwa 50.39M, was 96.24% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -14521914.00 gestiegen.